(Q35190098)

English

Efalizumab: an overview

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

Europe PubMed Central

Efalizumab: an overview (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

author name string

Craig L Leonardi

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

0 references

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Journal of the American Academy of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

2 Suppl

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

S98-104

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

The immunologic basis for the treatment of psoriasis with new biologic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901141-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901141-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The immunological synapse: a molecular machine controlling T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901141-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Remote T cell co-stimulation via LFA-1/ICAM-1 and CD2/LFA-3: Demonstration with immobilized ligand/mAb and implication in monocyte-mediated co-stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901141-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901141-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901141-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901141-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901141-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901141-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0190-9622(03)01141-1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35190098&oldid=1947499380"